{"id":41566,"date":"2025-09-16T17:12:32","date_gmt":"2025-09-16T09:12:32","guid":{"rendered":"https:\/\/flcube.com\/?p=41566"},"modified":"2025-09-16T17:12:33","modified_gmt":"2025-09-16T09:12:33","slug":"novo-nordisk-rybelsus-gains-cardio-benefit-from-soul-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41566","title":{"rendered":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial"},"content":{"rendered":"\n<p><strong>Novo\u202fNordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced that the <strong>European Medicines Agency (EMA)<\/strong>\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of <strong>Rybelsus\u00ae (oral semaglutide)<\/strong>, incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SOUL Trial<\/strong> \u2013 Enrolled patients with type\u202f2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD).<\/li>\n\n\n\n<li><strong>Cardiovascular Outcome<\/strong> \u2013 Oral semaglutide reduced major adverse cardiovascular events (MACE) by <strong>14\u202f%<\/strong> versus placebo.<\/li>\n\n\n\n<li><strong>Label Update<\/strong> \u2013 Rybelsus is now the <strong>first and only<\/strong> orally\u2011administered GLP\u20111 receptor agonist (GLP\u20111\u202fRA) in the EU with an evidence\u2011based cardiovascular benefit.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge<\/strong> \u2013 The cardio\u2011protective labeling differentiates Rybelsus from other GLP\u20111\u202fRAs, potentially expanding its share in the \u20ac6\u202fbillion\u2011plus T2D market.<\/li>\n\n\n\n<li><strong>US Expansion<\/strong> \u2013 A U.S. label extension for cardiovascular indication is expected later this year, aligning the two markets.<\/li>\n\n\n\n<li><strong>Patient Reach<\/strong> \u2013 The oral formulation removes injection barriers, improving adherence for patients with ASCVD or CKD\u2014a population at high cardiovascular risk.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-company-outlook\">Company Outlook<\/h4>\n\n\n\n<p>Novo\u202fNordisk\u2019s update underscores its commitment to evidence\u2011based diabetes care and positions the company at the forefront of cardiovascular\u2011centric endocrinology. The enhanced labeling is likely to strengthen prescriber confidence and accelerate uptake in both established and new markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41569,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,860,15],"class_list":["post-41566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-nyse-nvo","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41566\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial\" \/>\n<meta property=\"og:description\" content=\"Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41566\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T09:12:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-16T09:12:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial\",\"datePublished\":\"2025-09-16T09:12:32+00:00\",\"dateModified\":\"2025-09-16T09:12:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1609.webp\",\"keywords\":[\"Diabetes\",\"NYSE: NVO\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41566#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41566\",\"name\":\"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1609.webp\",\"datePublished\":\"2025-09-16T09:12:32+00:00\",\"dateModified\":\"2025-09-16T09:12:33+00:00\",\"description\":\"Novo\u202fNordisk A\\\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41566\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1609.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1609.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41566#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41566","og_locale":"en_US","og_type":"article","og_title":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial","og_description":"Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.","og_url":"https:\/\/flcube.com\/?p=41566","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-16T09:12:32+00:00","article_modified_time":"2025-09-16T09:12:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41566#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41566"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial","datePublished":"2025-09-16T09:12:32+00:00","dateModified":"2025-09-16T09:12:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41566"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41566#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","keywords":["Diabetes","NYSE: NVO","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41566#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41566","url":"https:\/\/flcube.com\/?p=41566","name":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41566#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41566#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","datePublished":"2025-09-16T09:12:32+00:00","dateModified":"2025-09-16T09:12:33+00:00","description":"Novo\u202fNordisk A\/S (NYSE: NVO) announced that the European Medicines Agency (EMA)\u2019s Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Rybelsus\u00ae (oral semaglutide), incorporating proven cardiovascular benefits demonstrated in the Phase\u202f3b SOUL trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41566#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41566"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41566#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","width":1080,"height":608,"caption":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41566#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo\u202fNordisk Rybelsus Gains Cardio Benefit from SOUL Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1609.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41566"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41566\/revisions"}],"predecessor-version":[{"id":41570,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41566\/revisions\/41570"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41569"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}